Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

MRI- vs CT-based Cervical Brachytherapy Costs

Brachytherapy; ePub 2018 Jan 10; Bajaj, et al

MRI-based cervical brachytherapy was less costly than CT-based brachytherapy, according to a study involving 40 individuals. Participants with Medicare underwent either MRI-based (4 fractions delivered in 2 implants; n=20) or CT-based (5 fractions delivered in 5 implants: n=20) high-dose-rate brachytherapy. Investigators looked at physician, hospital, and overall costs. Among the results:

  • MRI-based brachytherapy cost a median of ~$14,250.
  • CT-based brachytherapy with conscious sedation cost ~$18,300.
  • CT-based with deep sedation by an anesthesiologist cost ~$27,700.

The authors noted that their results show that cost does not need to be a barrier for MRI-based cervical brachytherapy, especially when delivering multiple fractions with the same application.

Citation:

Bajaj A, Harmon G, Weaver J, et al. A Medicare cost analysis of MRI- versus CT-based high-dose-rate brachytherapy of the cervix: Can MRI-based planning be less costly? [Published online ahead of print January 10, 2018]. Brachytherapy. doi:10.1016/j.brachy.2017.11.020.

This Week's Must Reads

Perioperative radiation therapy underused in elderly patients with soft tissue sarcomas, Venigalla S et al. Intl J Rad Oncology*Biology*Physics; September (102) 2018: 155-165. https://doi.org/10.1016/j.ijrobp.2018.05.019

Age, R0 resection, and adjuvant radiotherapy boost outcomes in myxofibrosarcoma, Boughzala-Bennadji R et al. Intl J Rad Oncology*Biology*Physics; October (102) 2018: 399-406. https://doi.org/10.1016/j.ijrobp.2018.05.055

Tumor size, invasion beyond subcutaneous fat predict adverse outcomes in undifferentiated pleomorphic sarcoma, Winchester D et al. J Am Acad Dermatol. Available online 19 May 2018 https://doi.org/10.1016/j.jaad.2018.05.022

High recurrence rate after pancreaticoduodenectomy for primary retroperitoneal sarcoma, Tseng W et al. European Journal of Surgical Oncology 2018 (44): June; 810-815.

Nivolumab, pembrolizumab successfully used in Kaposi sarcoma, Galanina et al. Cancer Immunol Res. 2018 Sept 7. doi: 10.1158/2326-6066.CIR-18-0121.

Must Reads in Practice Management

Feds move to streamline oversight of gene therapy, Collins FS and Gottlieb S. N Engl J Med. doi: 10.1056/NEJMp1810628

Better access means better survival for rural cancer patients, Unger JM et al. JAMA Network Open. 2018;1(4):e181235. doi: 10.1001/jamanetworkopen.2018.1235

Financial disclosures in oncology studies often incomplete, Wayant C et al. JAMA Oncol. 2018 Aug 30. doi: 10.1001/jamaoncol.2018.3738

Medicare ACO savings still possible without imposing penalties, McWilliams JM et al. N Engl J Med. doi: 10.1056/NEJMsa1803388

Burnout linked to lower quality patient care, Panagioti M et al. JAMA Intern Med. 2018 Sept 4. doi: 10.1001/jamainternmed.2018.3713.